| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2124813 | European Journal of Cancer | 2006 | 9 Pages |
Abstract
A benign safety profile, long serum half-life and low immunogenicity do warrant further exploration of adecatumumab for treatment of EpCAM-expressing neoplasia.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ralf Oberneder, Dorothea Weckermann, Beatrice Ebner, Cornelia Quadt, Petra Kirchinger, Tobias Raum, Mathias Locher, Nadja Prang, Patrick A. Baeuerle, Eugen Leo,